Aduhelm for Alzheimer’s Latest New Price by Biotech

Aduhelm for Alzheimer’s Drug Latest Update by Biotech

Aducanumab, marketed as Aduhelm for Alzheimer’s disease treatment for adults. The design is so convenient for patients with cognitive impairment(MCI) and mild dementia in their early stages of the disease. When it was first introduced in 2003, FDA approved it for Alzheimer’s patients. However,  later recommendation was just for those with mild cognitive impairment or mild dementia. In July 2021, the US Food and Drug Administration (FDA) updated the label for ADUHELMTM injectable 100 mg/mL solution. Since the FDA authorized the drug in June, despite a lack of evidence that it works, controversy has surrounded it. The active ingredient aducanumab was to be included in Aduhelm, which was to be sold as a concentrate for solution for infusion (drip) into a vein. IAduhelm is the only drug approved for Alzheimer’s in the US since 2003.

How Does Aduhelm for Alzheimer’s Works:

Aducanumab, the active ingredient in Aduhelm, is a monoclonal antibody (a type of protein) that binds to amyloid-beta, a protein that forms plaques in Alzheimer’s patient’s brains. The drug basically helps remove plaques and slow disease progression by binding to amyloid-beta.

Side Effects:

Although Aduhelm decreases amyloid beta in the brain, the European Medicines Agency highlighted that there was no evidence linking this impact to clinical benefit. Some major side effects of Aduhelm are as follows:
Swelling of brain areas, with or without tiny spots of bleeding in or on the brain surface (ARIA),
headache,
fall.

Precautions

Patients should inform their healthcare practitioner about all of their medical problems before receiving ADUHELM. This includes whether they are pregnant, planning to become pregnant, or breastfeeding. It is unknown whether ADUHELM will harm their unborn child or will pass into breast milk.
Aduhelm, a novel Alzheimer’s medicine, isn’t getting to a lot of people yet. Experts say that the high cost and many insurance companies are not willing to pay contribute to this issue. Moreover, some unanswered questions about whether it significantly improves memory loss are all contributing factors. Since the FDA authorized the drug in June, despite a lack of evidence that it works, controversy has surrounded it.

The business expressed the hope that the new $28,200 yearly pricing would increase patient access to the medicine.
In 2022, Biogen estimates that 50,000 patients will start therapy with Aduhelm due to insurance coverage and availability to diagnostics and specialized clinics.
Biogen also revealed cost-cutting initiatives through 2022, which may save the company $500 million per year. Biogen brought down the price down to $28,200. This much lower cost of such a useful medicine is itself a harbinger and hope for many patients.

Related Link: Aduhelm for Alzheimer’s Latest New Price by Biotech